share_log

Exicure | 8-K: Current report

Exicure | 8-K: Current report

Exicure | 8-K：重大事件
美股SEC公告 ·  09/30 16:48
Moomoo AI 已提取核心訊息
On September 27, 2024, Exicure, Inc., a biotechnology company specializing in spherical nucleic acid technologies, completed the sale of certain assets to Flashpoint Therapeutics, Inc. The assets include Exicure's technology related to spherical nucleic acids, research and development programs, and clinical assets. The sale resulted in gross proceeds of $1.5 million for Exicure. Additionally, Exicure will support Flashpoint Therapeutics in the development and licensing of the assets and will receive royalties from any future third-party licenses. The transaction was conducted at arm's length with no material relationship between the two companies outside of this agreement. In a separate event, Exicure expanded its Board of Directors from six to seven members and appointed Eui Yull Hwang as an independent director. Mr. Hwang's term will last until the 2025 annual meeting of stockholders. He will receive an annual retainer of $20,000 and is set to enter into the company's standard indemnification agreement.
On September 27, 2024, Exicure, Inc., a biotechnology company specializing in spherical nucleic acid technologies, completed the sale of certain assets to Flashpoint Therapeutics, Inc. The assets include Exicure's technology related to spherical nucleic acids, research and development programs, and clinical assets. The sale resulted in gross proceeds of $1.5 million for Exicure. Additionally, Exicure will support Flashpoint Therapeutics in the development and licensing of the assets and will receive royalties from any future third-party licenses. The transaction was conducted at arm's length with no material relationship between the two companies outside of this agreement. In a separate event, Exicure expanded its Board of Directors from six to seven members and appointed Eui Yull Hwang as an independent director. Mr. Hwang's term will last until the 2025 annual meeting of stockholders. He will receive an annual retainer of $20,000 and is set to enter into the company's standard indemnification agreement.
2024年9月27日，生物技術公司exicure完成了將部分資產出售給Flashpoint Therapeutics的交易。 這些資產包括exicure與球形核酸技術相關的技術、研發項目和臨床資產。 這筆交易實現了exicure 150萬美元的總收益。此外，exicure將支持Flashpoint Therapeutics開發和授權這些資產，並將從任何未來的第三方許可中獲得版稅。 這筆交易在兩家公司之間沒有其他重要關係的情況下進行。另外，exicure將董事會從六名擴大到七名，並任命了具有獨立董事身份的Eui Yull Hwang。 Hwang先生的任期將持續到2025年股東年會。 他將獲得2萬美元的年度保留費，並將簽署公司的標準保護協議。
2024年9月27日，生物技術公司exicure完成了將部分資產出售給Flashpoint Therapeutics的交易。 這些資產包括exicure與球形核酸技術相關的技術、研發項目和臨床資產。 這筆交易實現了exicure 150萬美元的總收益。此外，exicure將支持Flashpoint Therapeutics開發和授權這些資產，並將從任何未來的第三方許可中獲得版稅。 這筆交易在兩家公司之間沒有其他重要關係的情況下進行。另外，exicure將董事會從六名擴大到七名，並任命了具有獨立董事身份的Eui Yull Hwang。 Hwang先生的任期將持續到2025年股東年會。 他將獲得2萬美元的年度保留費，並將簽署公司的標準保護協議。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息